Continue reading this on our app for a better experience

Open in App
Floating Button
Home Capital Results

iX Biopharma reports loss for FY2022 despite eight-fold rise in revenue

Felicia Tan
Felicia Tan • 2 min read
iX Biopharma reports loss for FY2022 despite eight-fold rise in revenue
The revenue surge was mainly driven by the upfront payment received from the group’s Wafermine out-licensing deal with Seelos Therapeutics.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Specialty pharmaceutical company iX Biopharma has reported revenue of $14.4 million for the FY2022 ended June, an eight-fold, or 725% increase from its FY2021 revenue of $1.7 million.

The revenue surge was mainly driven by the upfront payment received from the group’s Wafermine out-licensing deal with Seelos Therapeutics, Inc. in November 2021.

iX Biopharma also registered revenue growth in its specialty pharmaceuticals segment, mainly contributed by medicinal cannabis product sales and services. However, its nutraceuticals segment saw lower revenue y-o-y due to supply chain and logistics disruptions in Australia and China as a result of Covid-19.

On the back of the out-licensing revenue and the improved underlying business activity, the group recorded gross profit of $12.3 million, versus a gross loss of $0.38 million in FY2021.

Despite the revenue surge, the group reported a net loss of $4.6 million for the FY2022, 44% narrower than the $8.2 million net loss in the year before.

The net loss includes a $1.9 million net currency exchange loss from the depreciation of the Australian dollar against the Singapore dollar during the year, as well as a downward adjustment of $3.3 million in the fair value of the quoted equity shares in Seelos that the group had received as part payment for the Wafermine out-licensing deal.

See also: Trump wins Republican nomination, setting up rematch with Biden

Loss per share stood at 0.62 cent on a fully diluted basis.

Excluding the foreign exchange loss and the fair value adjustment, the group would have recorded a profit before tax of $1.1 million.

As at June 30, cash and cash equivalents stood at $12.9 million.

Shares in iX Biopharma closed at 16.4 cents on Aug 22.

Highlights

Re test Testing QA Spotlight
1000th issue

Re test Testing QA Spotlight

Get the latest news updates in your mailbox
Never miss out on important financial news and get daily updates today
×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.